Key result
High platelet reactivity in STEMI is linked to ~36% lower rates of pre-PCI TIMI 2/3 flow.
Why the study?
Does high platelet reactivity (HPR) associate with worse coronary reperfusion prior to and after primary percutaneous coronary intervention in STEMI patients?
Observational (n=164)
Does high platelet reactivity (HPR) associate with worse coronary reperfusion prior to and after primary percutaneous coronary intervention in STEMI patients?
Absolute Event Rate: 32.5% vs 51.1%
p-value: p=0.04
In STEMI patients undergoing primary PCI, high platelet reactivity despite P2Y12 inhibitor pretreatment is associated with worse pre-PCI coronary patency, higher thrombotic burden, and worse post-PCI coronary reperfusion.
No takes yet. Share an insight, caveat, or question.
HPR signals impaired pre-PCI reperfusion in STEMI; hypothesis-generating for tailored antiplatelet strategies, should not yet change practice.
Capranzano et al. (2016) conducted an observational in ST-segment elevation myocardial infarction (STEMI) (n=164). High platelet reactivity (HPR) vs. Non-HPR was evaluated on Pre-PCI Thrombolysis in Myocardial Infarction (TIMI) flow grades 2 or 3 (p=0.04). High platelet reactivity in STEMI patients undergoing PPCI was associated with lower rates of pre-PCI TIMI flow grades 2 or 3 compared to non-HPR patients (32.5% vs. 51.1%, p=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: